Effect of Xuezhikang Combined with Statins on Lipid Metabolism and Vascular Endothelial Function in Patients with Primary Hyperlipidemia

Abstract

Abstract: Objective To investigate the clinical effect of combined treatment with Xuezhikang and statins in the treatment of primary hyperlipidemia and the effect on lipid metabolism and vascular endothelial function. Methods Clinical data of 72 patients with primary hyperlipidemia admitted to Rizhao Central Hospital from August 2021 to August 2022 were retrospectively analyzed. According to different medication methods, 36 cases receiving atorvastatin treatment were set as control group, and 36 cases receiving Xuezhikang combined with atorvastatin treatment were set as observation group. The clinical efficacy, lipid metabolism indexes, vascular endothelial function, inflammation levels, oxidative stress indexes and adverse reactions were compared between the two groups. Results The total effective rate of the observation group was higher than that of the control group, the levels of total cholesterol (TC), triglyceride (TG) and low density lipoprotein cholesterol (LDL-C) were lower than those of the control group, and the level of high density lipoprotein cholesterol (HDL-C) was higher than that of the control group after treatment (P<0.05). After treatment, nitric oxide (NO) level was higher than that of control group, endothelin (ET) level was lower than that of control group, and there were statistical differences (P<0.05). The levels of CRP, IL-6 and TNF-α in observation group were lower than those in control group after treatment,and there were statistical differences (P<0.05). After treatment,the malondialdehyde (MDA) level in observation group was lower than that in control group, while the glutathione peroxidase (GSH-Px), superoxide dismutase (SOD) and total antioxidant capacity (TAOP) levels in observation group were higher than those in control group, with statistical difference (P<0.05). There was no significant difference in adverse reactions between the two groups (P>0.05). Conclusion Xuezhikang combined with statins can improve the treatment effect of primary hyperlipidemia, correct lipid disorders, reduce inflammation and oxidative stress reaction, protect vascular endothelial function, safe and reliable.

Key words: primary hyperlipidemia, xuezhikang, atorvastatin, lipid metabolism, vascular endothelial function

CLC Number:

R972

MU Lei, LIN Jun-jian. Effect of Xuezhikang Combined with Statins on Lipid Metabolism and Vascular Endothelial Function in Patients with Primary Hyperlipidemia[J]. ZHONGHUA YANGSHENG BAOJIAN, 2023, 41(21): 16-20.

References

[1] 王晓梅,卢斯琪,左凯妮,等.降脂通络软胶囊治疗原发性高脂血症气滞血瘀证患者的有效性、安全性及经济性分析[J].世界中西医结合杂志,2022,17(5):1000-1004.
[2] 周琴,邱晓燕.瑞舒伐他汀联合硝苯地平治疗高血压合并高脂血症患者的疗效及对患者血清MCP 1、ICAM 1、ET 1水平的影响[J].医学临床研究,2019,36(10):1994-1996.
[3] 费香勇,刘贵.葛根芩连汤联合阿托伐他汀对老年冠心病合并高脂血症病人血脂水平的影响[J].中西医结合心脑血管病杂志,2020,18(2):212-215.
[4] 韩天云,刘梅,解冬千.稳心调脂汤联合阿托伐他汀对冠心病高脂血症患者血管内皮作用机制的研究[J].湖北中医药大学学报,2022,24(1):31-34.
[5] 张月,徐瑞霞,张彦,等.血脂康对高脂血症患者低密度脂蛋白颗粒和氧化型低密度脂蛋白的影响[J].中国动脉硬化杂志,2020,28(3):229-232.
[6] 武文峰,吴月,曾玉杰,等.血脂康在老年高脂血症患者中的应用[J].中华老年心脑血管病杂志,2020,22(8):844-846.
[7] 中国成人血脂异常防治指南修订联合委员会.中国成人血脂异常防治指南(2016年修订版)[J].中华健康管理学杂志,2017,11(1):7-28.
[8] 王学美. 《高脂血症中医诊疗指南(2008)》关键内容解读[J].中华全科医师杂志,2012,11(3):180-182.
[9] 王士兵,张海军,柯美琴,等.降脂颗粒联合阿托伐他汀治疗气滞血瘀型高脂血症的临床研究[J].中西医结合心脑血管病杂志,2021,19(24):4343-4345.
[10] 王晓会. 阿托伐他汀钙联合丹参川芎嗪注射液治疗冠心病心绞痛的临床疗效及对血清Fractalkine和血小板活化因子水平的影响[J].广西医科大学学报,2019,36(3):435-438.
[11] 王鸿燕,赵月娥.血脂康胶囊联合雷火灸对颈动脉粥样硬化患者血脂,血管内皮功能及相关因子蛋白的影响研究[J].湖南中医药大学学报,2020,40(4):473-477.
[12] 高凌俊. 血脂康胶囊联合依折麦布治疗老年高脂血症的疗效观察[J].中西医结合心脑血管病杂志,2019,17(17):2633-2634.
[13] 李婧,朱娅,王崑.血脂康胶囊联合普伐他汀治疗慢性心力衰竭的临床研究[J].现代药物与临床,2022,37(10):2276-2280.
[14] 于丽丽,廉炜,余晓英,等.氨氯地平联合阿托伐他汀钙治疗高血压合并冠心病患者的临床研究[J].中国临床药理学杂志,2021,37(20):2734-2737.
[15] 贺正波,束晨,张明玺.氨氯地平联合阿托伐他汀钙片对高血压合并冠心病病人免疫功能、血管内皮功能与炎症因子水平的影响[J].中西医结合心脑血管病杂志,2020,18(8):1276-1279.
[16] 李绪贵. 血脂康联合阿托伐他汀对老年高血压合并冠心病患者血压、血脂及炎性因子的影响[J].河北医药,2022,44(17):2667-2669.
[17] 王俊,张珍,邵加庆,等.血脂康对db/db糖尿病小鼠胰岛分泌功能和氧化应激影响的研究[J].中国糖尿病杂志,2015,23(2):169-173.